Misfolding & Disease

Ribosomopathies

Summary

Ribosomopathies are diseases caused by defects in ribosome biogenesis or function, manifesting with tissue-specific phenotypes including bone marrow failure and cancer predisposition.

Key Points

  • 1Ribosomopathies are caused by mutations in ribosomal proteins or biogenesis factors yet produce tissue-specific disease
  • 2The RPL5/RPL11-MDM2-p53 nucleolar stress checkpoint is the central pathogenic mechanism
  • 3Diamond-Blackfan Anemia (RPS19 mutations) is the prototype, causing pure red cell aplasia
  • 4Tissue specificity is explained by differential ribosome demand, specialized ribosomes, and extra-ribosomal RP functions
  • 5Cancer predisposition arises from chronic p53 stress selecting for p53-pathway escape mutations

Ribosomopathies are a class of human diseases caused by mutations in genes encoding ribosomal proteins (RPs) or ribosome biogenesis factors. Despite ribosomes being universally essential in every cell, these mutations produce remarkably tissue-specific phenotypes—a paradox that has driven intense research into ribosome biology and translational regulation.

The Central Paradox

Ribosomes are required by every cell for protein synthesis. Yet mutations in ribosomal components do not cause global cellular failure. Instead, they produce highly specific clinical presentations:

- Bone marrow failure (Diamond-Blackfan Anemia)

- Craniofacial defects (Treacher Collins Syndrome)

- Exocrine pancreatic insufficiency (Shwachman-Diamond Syndrome)

- Isolated macrocytic anemia (5q- Syndrome)

This tissue specificity has been explained by several complementary mechanisms, including differential ribosome demand, specialized ribosomes with tissue-specific RP compositions, and extra-ribosomal functions of individual RPs.

The p53-MDM2 Axis in Ribosomal Stress

The molecular link between ribosome dysfunction and disease centers on the nucleolar stress response:

Normal Conditions

  • Ribosomal proteins are synthesized in the cytoplasm and imported into the nucleolus
  • They assemble with rRNA to form ribosomal subunits

    • - The E3 ubiquitin ligase MDM2 continuously targets p53 for proteasomal degradation

  • This keeps p53 levels low in healthy cells

    • Ribosomal Stress

    When ribosome biogenesis is disrupted:

    1. Free (unincorporated) ribosomal proteins RPL5 and RPL11 accumulate

  • RPL5/RPL11 bind directly to MDM2, inhibiting its E3 ligase activity
  • p53 is stabilized and activated

    • 4. p53 drives cell cycle arrest (p21 induction) and apoptosis (PUMA, NOXA)

  • Rapidly dividing cells are disproportionately affected

    • This RPL5/RPL11-MDM2-p53 checkpoint acts as a surveillance mechanism ensuring that cells with defective translation machinery are eliminated rather than allowed to proliferate with potentially aberrant protein production.

    Diamond-Blackfan Anemia (DBA)

    DBA is the prototype ribosomopathy, providing the foundational understanding for the entire disease class.

    Genetics

  • Autosomal dominant; ~70% of cases have identified mutations

    • - RPS19 mutations account for ~25% of cases (first gene identified)

    - RPL5 and RPL11 are the next most common (~7% and ~5%)

  • Over 20 RP genes now implicated (both small and large subunit)

    • Clinical Presentation

    - Pure red cell aplasia presenting in the first year of life

  • Macrocytic anemia with reticulocytopenia
  • Congenital anomalies in ~50% (thumb malformations, craniofacial defects, cardiac anomalies)
  • Short stature

    • Why Erythroid Progenitors?

    Erythroid progenitors are exquisitely sensitive to ribosomal stress because:

  • They undergo extremely rapid proliferation during differentiation
  • Hemoglobin synthesis demands massive translational output
  • They may have lower thresholds for p53-mediated apoptosis
  • Specialized ribosome requirements for globin mRNA translation

    • Treatment

    - Corticosteroids: First-line therapy; ~80% initial response

    - Chronic transfusions: For steroid-refractory patients

    - Hematopoietic stem cell transplantation: Only curative option

    - Gene therapy: Under investigation using lentiviral RPS19 delivery

    Other Major Ribosomopathies

    Shwachman-Diamond Syndrome (SDS)

    - Caused by mutations in SBDS, a ribosome biogenesis factor required for 60S subunit maturation

    - SBDS facilitates release of the anti-association factor eIF6 from pre-60S subunits

  • Clinical triad: exocrine pancreatic insufficiency, bone marrow failure, skeletal abnormalities
  • Neutropenia is the most common hematological finding
  • High risk of progression to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)

    • Treacher Collins Syndrome (TCS)

    - Caused by mutations in TCOF1 (treacle) or POLR1C/POLR1D (RNA polymerase I/III subunits)

  • Treacle is essential for rRNA transcription and ribosome biogenesis in neural crest cells
  • Craniofacial defects: malar hypoplasia, micrognathia, ear anomalies, coloboma
  • Neural crest cells are uniquely sensitive due to high proliferative demands during embryogenesis
  • p53 activation in neural crest cells drives apoptosis; genetic p53 deletion rescues the phenotype in mice

    • 5q- Syndrome

  • Myelodysplastic syndrome caused by deletion of chromosome 5q31.2

    • - RPS14 haploinsufficiency drives the erythroid defect

  • Presents with macrocytic anemia, normal or elevated platelet counts, hypolobated megakaryocytes

    • - Lenalidomide is remarkably effective, targeting casein kinase 1α (CK1α) for degradation

    Cartilage-Hair Hypoplasia (CHH)

    - Caused by mutations in RMRP, a non-coding RNA component of RNase MRP

  • RNase MRP processes pre-rRNA (specifically ITS1 cleavage)
  • Short-limbed dwarfism, fine sparse hair, immunodeficiency
  • Enriched in Amish and Finnish populations (founder effects)

    • The Tissue Specificity Paradox

    Several models explain why ubiquitous ribosomal defects produce tissue-specific disease:

    Differential Ribosome Demand

  • Rapidly proliferating cells (hematopoietic progenitors, neural crest) require the highest rates of ribosome biogenesis
  • Even modest reductions in ribosome levels disproportionately affect these populations
  • Threshold model: each cell type has a different minimum ribosome requirement

    • Specialized Ribosomes

  • Not all ribosomes are identical—RP composition varies between tissues
  • Some mRNAs require specific RP compositions for efficient translation
  • Loss of a particular RP may preferentially affect translation of tissue-specific transcripts

    • Extra-Ribosomal Functions

  • Individual RPs have functions beyond translation
  • RPL11 regulates c-Myc transcription independently of ribosomes
  • RPS3 participates in DNA repair and NF-κB signaling
  • Loss of these moonlighting functions may contribute to tissue-specific phenotypes

    • mRNA-Specific Translation Effects

  • Ribosome haploinsufficiency does not affect all mRNAs equally
  • mRNAs with complex 5' UTR structures or IRES elements may be more sensitive
  • GATA1 (master erythroid transcription factor) translation is particularly affected in DBA

    • Cancer Predisposition

    Ribosomopathies carry an elevated risk of malignancy, creating a conceptual tension: how can defects in a tumor-suppressive pathway (p53 activation) predispose to cancer?

    The Chronic Stress Selection Model

  • Chronic ribosomal stress maintains persistent p53 activation
  • This creates strong selective pressure for cells that escape p53 surveillance

    • 3. Clonal evolution favors cells acquiring TP53 mutations or other p53-pathway defects

  • These p53-deficient clones have a proliferative advantage and are primed for malignant transformation

    • Cancer Associations

    | Ribosomopathy | Associated Malignancies |

    |---------------|------------------------|

    | DBA | AML, MDS, osteosarcoma, colon cancer |

    | SDS | MDS, AML |

    | Dyskeratosis Congenita | MDS, AML, squamous cell carcinoma |

    | 5q- Syndrome | AML (progression) |

    Therapeutic Horizons

    L-Leucine Supplementation

  • Activates mTOR signaling, enhancing global translation
  • Shown to improve anemia in DBA zebrafish and mouse models
  • Clinical trials underway

    • Targeting the p53 Response

  • Transient p53 inhibition could relieve the apoptotic block
  • Challenge: chronic p53 suppression increases cancer risk
  • Requires careful temporal and tissue-specific control

    • Gene Therapy

  • Lentiviral delivery of deficient RP genes to hematopoietic stem cells
  • Promising preclinical results for RPS19-deficient DBA
  • CRISPR-based correction of specific mutations under investigation
    • Previous
    Mass Spectrometry Proteomics
    Next
    Chaperone-Assisted Autophagy (CMA)